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Abstract 
Ample attention has been devoted to the construction of anti-cancer drug delivery systems with increased stabil-
ity, and controlled and targeted delivery, minimizing toxic effects. In this study we have designed a magnetically 
attractive hydroxyapatite (m-HAP) based alginate polymer bound nanocarrier to perform targeted, controlled and 
pH sensitive drug release of 6-gingerol, doxorubicin, and their combination, preferably at low pH environments (pH 
5.3). They have exhibited higher encapsulation efficiency which is in the range of 97.4–98.9% for both 6-gingerol and 
doxorubicin molecules whereas the co-loading has accounted for a value of 81.87 ± 0.32%. Cell proliferation assays, 
fluorescence imaging and flow cytometric analysis, demonstrated the remarkable time and dose responsive anti-pro-
liferative effect of drug loaded nanoparticles on MCF-7 cells and HEpG2 cells compared with their neat counter parts. 
Also, these systems have exhibited significantly reduced toxic effects on non-targeted, non-cancerous cells in contrast 
to the excellent ability to selectively kill cancerous cells. This study has suggested that this HAP based system is a ver-
satile carrier capable of loading various drug molecules, ultimately producing a profound anti-proliferative effect.
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Introduction
Doxorubicin is an extensively used first line chemothera-
peutic [1, 2] with an excellent effectiveness over a range 
of cancer types including breast cancer and liver cancer 
[3–7]. It is an anthracycline which exerts its anti-prolifer-
ation effect by intercalating with double stranded DNA, 
which could in turn arrest cell division and expression 
of vital proteins, and ultimately lead to cell death [4, 5]. 
However, later on it was observed that this particular 
drug is heavily associated with cardiotoxicity, neurotoxic-
ity, myelosuppression, non-targeted killing of normal or 
healthy cells, and the development of multi drug resist-
ance (MDR), which has restricted its clinical efficacy and 
given rise to the recurrence of the cancers [8–11]. It has 
also been observed that the conjugation of doxorubicin 
with nanoparticulate systems such as superparamagnetic 
iron oxide nanoparticles would be an ideal approach to 
minimize the MDR while leading to enhanced cytotoxic 
effect over the drug resistant cancer cells [12, 13].
In addition, as a replacement approach for doxoru-
bicin, the use of natural products as anti-cancer and 
cancer preventive agents has gained much attention 
over the past 30 years [14]. In this context, plant derived 
phytochemicals are preferred as they are generally less 
toxic and well tolerated by normal cells. These com-
pounds generally contain a pool of active compounds 
Open Access
Chemistry Central Journal
*Correspondence:  rohini@chem.cmb.ac.lk 
1 Department of Chemistry, University of Colombo, Colombo 00300, Sri 
Lanka
Full list of author information is available at the end of the article
Page 2 of 13Manatunga et al. Chemistry Central Journal          (2018) 12:119 
such as alkaloids, phenolics, tannins and flavonoids 
with very high activity, including anti-oxidant, anti-
inflammatory, anti-angiogenic, anti-microbial, anti-
cancer activity [15]. Curcumin, gingerol, β-carotene, 
quercetin and linamarine are some of the commonly 
investigated compounds of plant extracts that are very 
effective and heavily investigated for the safer develop-
ment of anti-cancer drugs [16–18].
6-Gingerol is a polyphenolic active ingredient of 
the ginger rhizome, Zingiber officinale [19, 20], which 
is capable of reducing the growth of many cancer 
types [17, 21, 22]. 6-Gingerol can interfere with num-
ber of cell signaling pathways that control the balance 
between the cell apoptosis and proliferation [23]. These 
beneficial effects have been mainly assessed for breast 
cancer and in liver carcinoma [19, 24]. Moreover, it has 
also shown anti-microbial, anti-viral, cardio-protective, 
anti-hyperglycemic, anti-lipidemic and immunomodu-
latory effects [25–27].
Nevertheless, 6-gingerol has various drawbacks such 
as temperature, pH, and oxygen sensitivity, light insta-
bility, and poor aqueous solubility, hindering its poten-
tial applicability [28, 29]. Therefore, the development 
of drug carrier systems for the safer delivery of 6-gin-
gerol in a targeted and controlled manner is highly 
essential. Therefore, attention has been devoted to the 
development of a nanoparticle based delivery for these 
compounds [30]. However, the use of carriers for the 
delivery of 6-gingerol is limited to a few studies [20, 26, 
28, 31].
The co-delivery approach of 6-gingerol with toxic 
chemotherapeutics such as doxorubicin and cis-platin 
is another area of 6-gingerol utilization as it could syn-
ergistically act along with these drug molecules due 
its chemo preventive and chemo sensitive properties 
[20]. 6-Gingerol has been very effective in the elimina-
tion of the problem of MDR, seen with many chemo-
therapeutics [32]. Furthermore, the synergistic effect of 
6-gingerol on neuroprotective, hepatoprotective, and 
anti-emetic properties has been exhibited when co-
administering with doxorubicin [25, 32–37].
Nevertheless, it is worth noticing that the use nano-
particle based targeted and controlled drug delivery 
carriers for the dual loading of doxorubicin and 6-gin-
gerol and enhancing their properties is not reported 
elsewhere. Therefore, in this study we have attempted 
to use a novel magnetic hydroxyapatite (m-HAP) nan-
oparticle system as an effective drug carrier for the 
controlled and pH sensitive delivery of 6-gingerol, dox-
orubicin and the dual drugs to inhibit the proliferation 
of breast and liver carcinoma cells targeting the devel-
opment of a universal type drug carrier.
Materials and methods
Materials
6-Gingerol (> 98.0%, HPLC), Doxorubicin hydrochlo-
ride (98.0–102.0%, HPLC), calcium nitrate tetrahydrate 
(Ca(NO3)2·4H2O, 99%, ACS), diammonium hydro-
gen phosphate ((NH4)2HPO4, > 99.0%), ammonium 
iron(II) sulfate hexahydrate ((NH4)2Fe(SO4)2·6H2O, 
99.0%, ACS), ammonium iron(III) sulfate dodecahy-
drate  (NH4Fe(SO4)2·12H2O, 99.0%, ACS), ethanol 
(EtOH, > 99.8%, HPLC), methanol anhydrous (MeOH, 
99.8%), alginic acid sodium salt (NaAlg, low viscosity), 
Cetyltrimethyl ammonium bromide (CTAB, > 98%) and 
 TWEEN®80 (Viscous liquid), and ammonium hydroxide 
solution (puriss. p.a., 25%  NH3 in  H2O) were purchased 
from Sigma Aldrich, Bangalore, India. Polyethylene gly-
col 200 (PEG 200) was purchased from Merck Millipore 
Corporation, Darmstadt, Germany. Snakeskin dialysis 
tubing (MWCO 3.5 kDa) was purchased Thermo Fisher, 
Bangalore, India.
Cell lines and reagents
MCF-7 breast carcinoma cell line and HEpG2 hepatocel-
lular carcinoma cell line were purchased from ECACC 
(Salisbury, UK) and cultured in complete DMEM (Gibco, 
UK). The DMEM medium was supplemented with 10% 
fetal bovine serum (FBS, Gibco, USA), 100 U/mL of peni-
cillin and 100 μg/mL of streptomycin, 1% 200 mM l-glu-
tamine (Gibco, USA) and 1% non-essential amino acids 
(NEAA, 100×, Gibco, USA) whereas the RPMI medium 
(RPMI 1640, Gibco, UK), supplemented with 10% FBS, 
1% l-glutamine, and 1% penicillin/streptomycin, was 
used to culture HEpG2 cells. Both cell cultures were 
maintained at 37 °C in a humidified 5%  CO2 atmosphere.
To assess the effect of these nanoparticles on non-
targeted cells, African Green monkey kidney epithelial 
cell line, Vero (ATCC, USA) was purchased and grown 
in DMEM medium containing 10% FBS, 1% penicillin/
streptomycin, 1% l-glutamine, 1% NEAA and 1% 1  M 
 NaHCO3 under standard cell culture conditions. Passag-
ing of all three cell lines was carried out every 3–4 days 
using 0.05% Trypsin EDTA.
Preparation of magnetic HAP (m‑HAP) and in vitro loading 
of drug molecules
Briefly, PEG coated IONPs were prepared using 25.0 mL 
of 0.1  M iron precursor solutions with 2:1  (Fe3+:Fe2+) 
which were later functionalized with sodium alginate 
polymer molecules (0.500 g of PEG coated IONPs mixed 
with 40% w/v of sodium alginate). HAp nanoparticles 
were allowed to be generated as a coating on the alginate-
IONPs to obtain magnetic HAP as specified in our previ-
ous work [38]. 6-Gingerol and doxorubicin were selected 
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as the potential anti-cancer drug and a positive control 
respectively. Their individual loading and the combina-
tional loading was carried out using m-HAP as a drug 
carrier material. The 6-gingerol loading procedure was 
similar to the process specified by our group in previ-
ous work [38] and the obtained product is labelled as 
6-Gin-m-HAP.
In addition, the loading of doxorubicin onto m-HAP 
involved the incubation of 0.06  g/mL m-HAP solution 
with 66.67 mL of 25 ppm aqueous doxorubicin. HCl solu-
tion provided with mild stirring for 17 h at 37 °C. Doxo-
rubicin loaded m-HAP (Dox-m-HAP) was magnetically 
separated, and the unbound doxorubicin content was 
determined via fluorescence spectroscopy [39], λexcitation 
at 467 nm and λemission at 589 nm, HORIBA fluorescence 
spectrophotometer).
For the dual loading of 6-gingerol and doxorubicin 
(6-Gin + Dox-m-HAP), m-HAP loaded with 6-gingerol 
(23.0 mg of 6-gingerol dissolved in methanol) was sepa-
rated from the original solution and incubated with the 
25 ppm doxorubicin solution for 17 h at 37 °C.
To assess the amount of 6-gingerol loaded into 6-Gin-
m-HAP and 6-Gin + Dox-m-HAP, an analysis of the 
samples was carried out using UV Visible spectroscopy 
(Grant XUB5, Grant Instruments) at 291 nm which cor-
responds to the λmax of desorbed 6-gingerol in methanol 
medium [38].
From the results obtained for the loaded 6-gingerol 
and doxorubicin, from the UV measurements and fluo-
rescence spectroscopy, respectively, the two important 
parameters of the drug carrier, which are the loading 
capacity and the loading efficiency were calculated [40].
To measure the drug release from these formulations, 
10.0  mg of the drug loaded nanoparticles were inserted 
into a dialysis bag (MWCO 3500) and incubated in 
20 mL of PBS buffer (pH 7.4, PBS:MeOH = 9:1) and ace-
tate buffer (pH 5.3, Ace:MeOH = 9:1) at 37  °C provided 
with mild shaking (80  rpm) over a period of time. At 
regular time intervals, 0.5 mL aliquots of the sample were 
withdrawn from the solution and replaced with the fresh 
buffer. The amount of released 6-gingerol and doxoru-
bicin was analyzed according to the procedure specified 
above. The cumulative drug release in each drug system 
was calculated. All the studies were carried out in tripli-
cate in three individual experiments.
Characterization of m‑HAP, 6‑Gin‑m‑HAP, Dox‑m‑HAP, 
6‑Gin + Dox‑m‑HAP
The size and the morphology of the m-HAP, 6-Gin-
m-HAP, Dox-m-HAP and 6-Gin + Dox-m-HAP were 
acquired using a transmission electron microscope 
(TEM, JEOL JEM-2010 High resolution transmission 
electron microscope, Japan) operating at 80  kV. The 
different functional groups of the carrier and the drug-
carrier molecules were identified using Fourier transform 
infra-red (FT-IR) spectroscopy (Bruker Vertex 80, Ger-
many) via the diffuse reflectance mode, within the spec-
tral range 400–4000 cm−1. Further, the interaction of the 
drug molecules with the carrier was studied using X-ray 
photoelectron spectroscopic (XPS) analysis (a K-alpha 
instrument, Thermo Scientific, East Grinsted, UK, 
equipped with a monochromated Al Kα X-ray source was 
used with a pass energy of 40 eV and step size of 0.1 eV). 
Spectra were processed using the CasaXPS software 
(Casa Software Ltd., Teignmouth, UK).
In‑vitro cytotoxicity assessment
The in  vitro cytotoxicity of different formulations 
(m-HAP, 6-Gin-m-HAP, Dox-m-HAP and, 6-Gin + Dox-
m-HAP) on MCF-7 breast cancer cells and HEpG2 liver 
cancer cells was assessed using WST-1 cell proliferation 
detection assay [41]. Briefly, cells were seeded in 96-well 
plates (Greiner CELLSTAR ®) at a density of 3 × 103 cells/
well [42–44] and they were cultured overnight in the 
respective media under standard cell culture conditions. 
The cells were then incubated with different concen-
trations of drugs and nanoparticles for 24, 48 and 72 h. 
Subsequently, 10  µL of the WST-1 solution (Abcam, 
ab155902, UK) were added to each well, and the cells 
were incubated for 0.5–4  h in standard culture condi-
tions without the removal of the media. Later, absorb-
ance values were recorded with an ELISA plate reader 
(MPScreen MR-96A) at 450  nm with a reference wave-
length at 630  nm. Experiments were performed in trip-
licate in three individual experiments. The percentage 
inhibition was obtained as given in the following equa-
tion (Eq. 1) [45].
Acell and  A(cells+ nanoparticles) are the absorbance values for 
the untreated cells and those treated with the nanoparti-
cles, respectively.  Ablank is the absorbance of the medium 
only. Triplicate data from three individual experiments 
were used to calculate the inhibitory concentration 
(IC)50 using GraphPad Prism 5 software (GraphPad Soft-
ware Version 7.02, USA).
In‑vitro cellular uptake studies
Cells were seeded in 8 well chamber slides  (Nunc® Lab-
Tek® Chamber Slide™) with a density of 2.5 × 104 cells/
well [42] overnight under standard cell culture condi-
tions. The cells were then treated with  1C50 values of 
6-Gin-m-HAP, Dox-m-HAP and 6-Gin + Dox-m-HAP 
(1)
Percentage cell inhibition (%)
= 1−
Acells+ nanoparticles − Ablank
Acells − Ablank
× 100%
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for 24, 48 and 72  h. All the experiments were carried 
out in triplicate, and after each incubation the cells were 
washed twice with cold PBS and then fixed with 3.7% par-
aformaldehyde S (VWR, UK) for 15  min prior to stain-
ing. The fixed cells were washed and stained with AO/EB 
(100 µg/mL) dual staining for 10 min under dark condi-
tions [43]. Similarly, for Hoechst staining the fixed cells 
were washed and treated with 5 µg/mL Hoechst (Thermo 
Fisher Scientific, Life Technologies) for 15 min [44]. After 
each incubation the stained cells were visualized under 
the fluorescence microscope (Olympus, FSX100).
Flowcytometric analysis of apoptotic induction
A quantitative measurement on apoptosis was obtained 
via flow cytometric analysis which required Annexin V 
APC and Zombie green dual staining protocol of cells 
[46]. The cells were seeded at a density of 1.5 × 105 cells/
well in a 24 cell well plate overnight under standard cell 
culture conditions. The medium was replaced with media 
containing the nanoparticles corresponding to the  IC50 
values of each system. The incubation was continued for 
18 h. Then the cells were trypsinized, centrifuged, washed 
and the pellet was treated with 0.5 µL of Zombie green 
for 30  min at room temperature. This was then washed 
with 2% FBS in PBS and subjected to Annexin V staining 
(195 µL of Annexin V binding buffer and 5 µL Annexin 
V APC) for 10  min at room temperature. All the steps 
were carried out under dark conditions. At the end of the 
staining the cells were immediately analyzed using flow 
cytometer (Guava-easyCyte flowcytometser, Merck). The 
cells devoid of nanoparticles and treated only with media 
served as the control. All the samples were run in trip-
licate. The data were analyzed by FCS express version 4 
(denovo software).
Evaluation of the effect on non‑cancerous mammalian cells
It is also important to detect whether these nanoparticles 
could selectively act on cancerous cells, providing a least 
or no effect on the non-targeted cells during the delivery. 
For this purpose, the cytotoxicity of bare nanoparticles 
and the drug loaded nanoparticles on a non-cancerous, 
epithelial cell line, i.e., Vero cell line, was evaluated [47, 
48]. The cells were seeded at a cell density of 1 × 103 cells/
well in a 96 well plate and on the following day they were 
treated with a series of different concentrations of nano-
particles and further incubated for another 24 h. At the 
end of the incubation, cell viability was assessed via the 
WST-1 cell viability assessment assay as specified earlier. 
All the samples were analyzed in triplicate.
Statistical analysis
The data were presented as the mean ± SEM. One-way 
analysis (ANOVA) of variance was used to determine sta-
tistical significance of the cumulative release rate and cell 
viability followed by Tukey–Kramer post hoc test analysis 
of variance. P values < 0.05 were considered statistically 
significant. All statistical analyses were performed using 
SPSS version 19 (IBM Corporation, Armonk, NY, USA).
Results and discussion
Morphological characterization of 6‑Gin‑m‑HAP, 
Dox‑m‑HAP, and 6‑Gin + Dox‑m‑HAP
According to TEM images  in Fig.  1, neat nanoparti-
cles (m-HAP) have sizes ranging from 10 to 20  nm; with 
drug loading the nanoparticles tend to increase in size. 
It is observed that the 6-Gin-M-HAP, Dox-m-HAP and 
6-Gin + Dox-m-HAP nanoparticles are in the sizes of 
21.6 ± 1.5 nm, 28.2 ± 2.1 nm and 32.1 ± 4.3 nm respectively. 
It can be seen that the presence of 6-gingerol or doxorubicin 
has given rise to an enlarged agglomerated nature (Fig. 1).
Surface functionalization characterization via FT‑IR and XPS 
studies
FT-IR spectra obtained for the four systems are given 
in Fig.  2, where Fig.  2a, b display the FT-IR spectra for 
neat drug carrier and the neat 6-gingerol, respectively. 
Fig. 1 TEM images of a neat drug carrier (m-HAP), b 6-Gin-M-HAP, c Dox-m-HAP and d 6-Gin + Dox-m-HAP
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After loading of 6-gingerol onto m-HAP (Fig. 2c), peaks 
corresponding to –CH2 stretching are clearly appear-
ing at 2914  cm−1 and 2877  cm−1. The rest of the peaks 
resemble the m-HAP spectrum with some additional 
peaks [49]: a small hump at 1719  cm−1 corresponding 
to –C=O stretching [26], and a few bands at 1398 cm−1, 
1247  cm−1, 1110  cm−1, and 891  cm−1 corresponding 
to aromatic C–H in-plane deforming and stretching, 
–C–O–C stretching, and –C–O stretching of –C–O–H 
bonds, respectively [50, 51].
The disappearance of the broad –NH2 stretching band 
at 3332  cm−1 of doxorubicin (Fig.  2d) in Dox-m-HAP 
(Fig. 2e) is in good agreement with the doxorubicin inter-
acting with the drug carrier [52]. In Fig.  2e the appear-
ance of a band at 1616  cm−1 [53] and a weak band at 
1287  cm−1 corresponding to carbonyl and –C–O–C– 
stretching vibration respectively of the doxorubicin fur-
ther confirmed the incorporation of doxorubicin into the 
nanoparticles [54].
When both 6-gingerol and doxorubicin were co-loaded 
to the m-HAP (Fig. 2f ), most of the bands in the finger-
print region of doxorubicin and 6-gingerol appear weak, 
due to the restriction of bond vibration when they are 
blended together in nanoparticles [55].
In Fig.  3a–c, the XPS data of C1s, O1s and N1s 
obtained for Dox-m-HAP, 6-Gin-m-HAP and 
6-Gin + Dox-m-HAP are presented. In Dox-m-HAP 
(Fig. 2a) system, the peak at 283.72 eV would arise due 
to the –C=C/C–C [56] of doxorubicin with slight shift 
due to the cation–π interactions. The peak appearing at 
286.69  eV could be due to the –C–N bonds resulting 
from doxorubicin [57] or –C–O–C– bonds of alginate 
or doxorubicin [58]. In addition, C1s peaks at 287.26 eV 
and 290.36  eV would appear due to –C–O–H of algi-
nate [59] and O=C– bonds of doxorubicin/alginate 
respectively [60]. Regarding the O1  s spectrum, the 
peak at 532.79 eV could appear from the O=C– bonds 
of doxorubicin or alginate [59], or the adsorbed water 
[61]. Furthermore, the peaks appearing at 531.35  eV 
and 529.39  eV would be accounted for as the –O– of 
HAP [62, 63] or the O=C–C– of doxorubicin [64]. Evi-
dence for the presence of –C–N bond of doxorubicin 
was seen in the N 1 s spectrum and it could be expected 
that the decrease of the peak position by few eVs would 
arise due to the binding of doxorubicin to  Ca2+ due 
to the transfer of the electron density of N–Ca2+ ions, 
similar to what was observed with the Au–N interac-
tion in previous studies [57].
In system 6-Gin-m-HAP (Fig.  3b), a C1s peak at 
284.94 eV is also present due to –C=C– binding energy 
[56] or due to –C–H bonds of CTAB molecules [65]. 
However, a slight increase of the binding energy can be 
accounted for by the reduction of electron density by the 
electron attracting groups around carbon atoms. The 
presence of gingerol is also indicated by the O1s binding 
energy peak corresponding to O=C– bonds at 532.41 eV 
[59]. Further, presence of quaternary amines of CTAB 
will lead to N1s peak at 400.26 eV [65, 66] with a shift to 
indicate electrostatic interaction with the alginates.
In the 6-Gin + dox-m-HAP system, C1s peaks at 
288.13  eV, 286.74  eV, and 288.13  eV suggest the pres-
ence of O=C– of doxorubicin [60], C–N of doxorubicin/
CTAB [65, 67] and C=O of gingerol/alginate, respec-
tively [58, 59]. The presence of doxorubicin and gingerol 
was further indicated by the O1s peak at 532.73 eV corre-
sponding to O=C–O [58, 59]. Evidence for the presence 
of various nitrogen environments was provided by N 1 s 
peaks appearing at 400.10  eV, 397.23  eV, and 395.37  eV 
corresponding to –C–N of CTAB [65, 67], –C–N of 
doxorubicin [64, 67] and the formation of –N=N– bond 
(NIST) between the nanoparticle bound cross-linked 
doxorubicin molecules. The XPS analysis of neat drug 
carrier (m-HAP) is given in Additional file 1: Fig. S1.
Assessment of the drug loading ability of m‑HAP drug 
carrier
The drug loading ability of m-HAP was also quantified by 
measuring the drug loading capacity (DL) and the drug 
encapsulation efficiency (EE) for each system. The result-
ing DL values and EE values are given in the Table 1, and 
reveal that the DL capacity has increased in 6-Gin + Dox-
m-HAP, where they are co-fabricated together, compared 
to the 6-Gin-m-HAP system. This could be due to the 
favorable interactions among 6-gingerol and doxorubicin 
molecules.
Fig. 2 FT-IR characterization of a m-HAP, b neat 6-gingerol, c 
6-Gin-m-HAP, d neat doxorubicin, e Dox-m-HAP, f 6-Gin + Dox-m-HAP
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In vitro drug releasing studies of 6‑Gin‑m‑HAP, Dox‑m‑HAP 
and 6‑Gin + Dox‑m‑HAP
The in  vitro drug release profiles of loaded drugs are 
given in Additional file 1: Fig. S2. In-contrast to the neat 
drugs which displayed a rapid and a complete release, 
when the drug was releasing from m-HAP the releasing 
pattern for both 6-gingerol and doxorubicin displayed 
a bi-phasic mode, of which the initial 1–6  h accounted 
for a burst release followed by a much slower, sustained 
release [68]. It was also noticeable that this release is pre-
ferred at low pH (pH 5.3) than at neutral pH, highlight-
ing the pH sensitivity of the carrier, m-HAP [38]. The 
Fig. 3 XPS analysis of drug loaded nanoparticle systems with the corresponding binding energy spectra for C1s, O1s and N1s: a Dox-m-HAP, b 
6-Gin-m-HAP and c 6-Gin + Dox-m-HAP
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release of 6-gingerol, at 5.3 pH after an incubation period 
of 96 h, was 99.48 ± 0.70% for the singly loaded situation, 
while it was 99.46 ± 0.63% when co-loaded with doxoru-
bicin, after an incubation period of 168 h.
As far as releasing doxorubicin from the carrier is con-
cerned, a low drug release percentage of 49.37 ± 0.85% 
and 14.28 ± 0.54% were recorded when singly loaded and 
co-loaded with 6-gingerol, respectively. This could be 
attributed to strong interactions of doxorubicin with algi-
nate, HAp and iron oxide such as electrostatic and van 
der Waals interactions, and H-bonding [69, 70]. Also the 
release of doxorubicin could be retarded due to the com-
petition that would build up between the doxorubicin 
and 6-gingerol in the co-loaded situation.
In‑vitro cytotoxicity assessment
In order to verify the anti-proliferative potential of these 
drug nano-conjugates, proliferation inhibition assays 
were conducted over three time points: 24, 48 and 72 h. 
The corresponding dose responsive and time responsive 
curves for 6-gingerol and doxorubicin systems over the 
two cell lines are given in Additional file 1: Figs. S3 and 
S4, whereas Fig. 4 show the time and dose response activ-
ity of the 6-Gin + Dox-m-HAP system on the same cell 
lines. The calculated  IC50 values are given in Table 2.
In general, it is clear that neat doxorubicin and Dox-
m-HAP are very potent in their activity, leading to very 
low  IC50 values with respect to other systems acting 
on both MCF-7 and HEpG2 cells. However, there is a 
significant increase in activity when drugs are loaded 
onto m-HAP nanoparticles, in contrast to the neat 
drug. This could be due to the remarkable ability of the 
Table 1 Drug loading capacities and  encapsulation 
efficiencies of drug loaded into m-HAP
System DL (%) EE (%)
6-Gin-m-HAP system 3.77 ± 0.55 98.8 ± 0.05
Dox-m-HAP system 23.0 ± 0.33 97.4 ± 0.12
6-Gin + Dox-m-HAP system 20.0 ± 0.12 81.9 ± 0.32
Fig. 4 Dose response and time response curves of MCF-7 and HEpG2 cells treated with 6-gingerol, doxorubicin and 6-Gin + Dox-m-HAP. a–c 
Effect of these systems on MCF-7 cells over 24, 48 and 72 h. d–f Effect of these systems on HEpG2 cells over 24, 48 and 72 h. Results are given as 
mean ± SD, n = 3
Table 2 Corresponding  IC50 values for each drug system at 24, 48 and 72 h incubation with cells
Drug system IC50 on MCF‑7 cells (µg/mL) IC50 on HEpG2 cells (µg/mL)
24 h 48 h 72 h 24 h 48 h 72 h
m-HAP Inactive Inactive Inactive Inactive Inactive Inactive
6-Gingerol 150.5 ± 10.6 102.4 ± 2.9 67.4 ± 6.9 118.9 ± 8.2 115.0 ± 7.9 32.1 ± 7.4
6-Gin-m-HAP 2.25 ± 0.73 1.38 ± 0.30 0.81 ± 0.17 44.9 ± 7.5 24.4 ± 7.8 3.43 ± 2.60
Doxorubicin 2.96 ± 0.96 3.03 ± 0.96 1.09 ± 0.46 53.0 ± 0.2 14.9 ± 4.1 1.14 ± 0.31
Dox-m-HAP 0.53 ± 0.15 0.43 ± 0.15 0.16 ± 0.05 7.69 ± 1.73 7.28 ± 2.19 0.58 ± 0.24
6-Gin + Dox-m-HAP 0.58 ± 0.07 0.53 ± 0.12 0.45 ± 0.09 0.55 ± 0.19 0.47 ± 0.05 0.19 ± 0.06
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carrier molecules to penetrate the cell membranes and 
to extend the activity [71].
When consider the effect of the 6-Gin + Dox-m-HAP 
system on MCF-7 cells (Fig. 4a–c and Table 2), it is as 
active as the Dox-m-HAP system (Additional file 1: Fig. 
S3), while maintaining a better activity than 6-Gin-m-
HAP, neat doxorubicin and neat 6-gingerol. The equal 
behavior of these two drug formulations suggests 
that the major effect is coming from the Dox-m-HAP 
system.
However, this system has been very promising against 
HEpG2 cells by having lowered  IC50 values with respect 
to all the other drug systems (Fig. 4, Additional file 1: Fig. 
S4 and Table 2). This emphasizes that this combinational 
delivery system is more effective against HEpG2 cells 
than MCF-7 cells. This may result from the synergistic 
effect of those two compounds which will enhance the 
cytotoxic activity on cancer cells [32].
Nevertheless, this type of a combinational approach 
highlights the novelty of this work as there are no reports 
on the use of a nanoparticle based drug carrier for the co-
delivery of both 6-gingerol and doxorubicin for the treat-
ment of cancer, more specifically the treatment of liver 
and breast cancer.
Fluorescence imaging of cellular uptake and damage
The  IC50 value was used to assess the cell damage that is 
induced by the neat drug or the drug loaded nanoparti-
cles on MCF-7 and HEpG2 cells for 24–72 h. The mor-
phological and nuclear changes that take place, detected 
via a fluorescence staining protocol (i.e., use of Hoechst 
and AO/EB staining), indicated that the apoptosis induc-
tion ability of 6-gingerol has been enhanced by load-
ing onto the m-HAP carrier (Additional file  1: Fig. S5a, 
b). However, these cells have displayed reduced volume, 
round shaped cells, and brighter nuclei with Hoechst 
[72], and bright yellow to red orange nuclei with AO/EB 
staining [73], confirming that a major proportion of cells 
are affected and have lost cellular integrity.
Likewise, when the doxorubicin system is considered 
(Additional file  1: Figs. S6a–c, S7a–c), Dox-m-HAP has 
been far superior to 6-Gin-m-HAP in exhibiting reduced 
remaining cell count with time. This could be due to the 
removal of dead cells during the staining procedure due 
to the loss of adherence. This is further demonstrated by 
the reduction of intensity of Hoechst stained cells.
A marked effect was also observed with the co-fabri-
cated system indicating its enhanced activity over neat 
doxorubicin and 6-gingerol, with more of the cells under-
going apoptosis and loss of attachment, and thereby 
reducing the remaining cells (Fig.  5a, b and Additional 
file 1: Fig. S8a, b).
Quantitative apoptotic detection via flow cytometry
In vitro anti-tumor activity of drug loaded nanoparticles 
was also quantitatively assessed by categorizing the cell 
population into different stages using flow cytometry. 
As shown in Fig. 6, a very few necrotic, debris or apop-
totic cells could be detected in untreated cells where 
most of them remain viable. In contrast, when the cells 
are treated with free drug or the drug loaded nanopar-
ticles, there is a clear shift of the cells from viable to 
apoptotic, late apoptotic and necrotic stages, decreasing 
the viable cell count. This is observed with doxorubicin, 
Dox-m-HAP, 6-Gin-m-HAP, and 6-Gin + Dox-m-HAP 
treated cells of both cell lines (Fig.  6, Additional file  1: 
Fig. S9a, b). It is clear that, with respect to the free drugs 
and singly loaded systems, the co-fabricated system (i.e., 
6-Gin + Dox-m-HAP) has led to a higher percentage 
of apoptotic, late apoptotic and necrotic cells, amount-
ing to 49.05 ± 0.33% and 52.12 ± 0.78% for MCF-7 and 
HEpG2 cells, respectively (Fig. 6). The effect produced by 
6-Gin + Dox-m-HAP is significant (0.05 < P) which could 
arise due to the synergistic effect of 6-gingerol increasing 
the anti-proliferative effect of doxorubicin [32]. However, 
it demonstrated that the cell viability results further rep-
resent the findings of cytotoxicity assays and fluorescence 
imaging studies.
Cytotoxic effects on non‑cancerous Vero cells
According to the dose response curves given in Addi-
tional file 1: Fig. S10a, b, it is clear that the free 6-gingerol 
and doxorubicin have produced very high toxicity on 
Vero cells and that this effect has been drastically reduced 
when these drugs have been incorporated into the 
m-HAP nanoparticles. This effect is much more evident 
with the increase in the concentration of the drug loaded 
nanoparticles. And importantly they have maintained 
a higher cell viability in the range of concentration that 
has been effective against the MCF-7 cells and HEpG2 
cells. Further, it is evident that when the drugs are co-fab-
ricated, as 6-Gin + Dox-m-HAP (Fig.  7), toxicity is con-
siderably reduced compared to the singly loaded systems. 
All these results suggest that these drug loaded nanopar-
ticles produce more effects selectively on cancer cells, 
while minimizing the effects on non-cancerous cells.
Conclusions
In this work we have successfully prepared 6-Gin-m-
HAP, Dox-m-HAP and 6-Gin + Dox-m-HAP for the 
targeted and controlled release of 6-gingerol and doxoru-
bicin and their combinations in a pH sensitive manner. 
The TEM results and surface characteristics provided 
by FT-IR and XPS analysis confirmed the interaction 
of drug molecules with m-HAP. The slow release of the 
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Fig. 5 Phase contrast (PC) and fluorescence images obtained to assess the effect of 6-gingerol, doxorubicin and 6-Gin + Dox-m-HAP on a MCF-7 
cells, b HEpG2 cells incubated for 72 h. Scale bar is 40 µm
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Fig. 6 Flow cytometric analysis of apoptotic induction of MCF-7 and HEpG2 cells by 6-gingerol, doxorubicin and 6-Gin + Dox-m-HAP after staining 
with Annexin V (ANX) and Zombie green (ZGR) dyes.  ANX−/ZGR+: necrotic or debris cells;  ANX+/ZGR+: late apoptotic cells;  ANX−/ZGR low: viable; 
 ANX+/ZGR dim: apoptotic cells. Numbers in each quadrant represent the percentage of cells (data are given as mean ± SD of triplicate experiments)
Fig. 7 Cell viability of Vero cells after treating with doxorubicin, 6-gingerol and 6-Gin + Dox-m-HAP for 24, 48 and 72 h
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drug molecules, preferably in a low pH environment (pH 
5.3), further exhibited the pH responsiveness at the sites 
of the cancer cells. Furthermore, it has been shown that 
6-Gin-m-HAP, Dox-m-HAP and co-loaded 6-Gin + Dox-
m-HAP have a potent inhibitory effect on both breast 
and liver cancer cells to a greater extent than the free 
doxorubicin and free 6-gingerol molecules. The cell pro-
liferation assays conducted on MCF-7 cells and HEpG2 
cells suggested that the anti-cancer effect of 6-gingerol is 
much enhanced when incorporated into the nanocarrier 
system. Additionally, the results obtained from the cell 
proliferation assays, fluorescence imaging and flow cyto-
metric analysis, showed that the combinational approach 
of both 6-gingerol and doxorubicin in m-HAP has dem-
onstrated much enhanced activity over MCF-7 and 
HEpG2 cancer cells, suggesting the chemosensitive activ-
ity of 6-gingerol on doxorubicin. And this effect could be 
identified as beneficial, as it could reduce the amount of 
doxorubicin used and thereby its associated toxic effects. 
Additionally, cell proliferation detection assays carried 
out on Vero cells highlighted that these drug loaded nan-
oparticles would have no or low cytotoxicity on non-tar-
geted cells. Therefore, this work highlights the possibility 
of developing new drug carrier systems for the effective 
delivery of anti-cancer agents like doxorubicin together 
with 6-gingerol like chemo preventive agents, to induce 
higher anti-proliferative activity while minimizing the 
drawbacks observed with doxorubicin.
Additional file
Additional file 1. XPS analysis, cumulative drug release percentages, dose 
responsive and time response curves and flow cytometry data.
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